On Mar 20, 2018, CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, today announced the official opening of its new manufacturing facility in Suzhou, China.
Located in Suzhou’s BioBAY Park, the new CMAB facility will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products.
Initially, the facility will generate pre-clinical and early-stage clinical (Phase I/II) products for Chinese and global clients, using manufacturing that follows global Good Manufacturing Practices (GMP) standards, including those of the China Food & Drug Administration, US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards.
CMAB in January completed its series A financing of US$38 million, which was led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium.
CMAB is a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Its adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical product today.